12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga · 03/18 12:05
Gainers
- Satellos Bioscience (NASDAQ:MSLE) stock rose 32.7% to $9.7 during Wednesday's pre-market session. The company's market cap stands at $150.7 million.
- Ovid Therapeutics (NASDAQ:OVID) shares moved upwards by 26.86% to $2.55. The market value of their outstanding shares is at $143.1 million. As per the news, the Q4 earnings report came out today.
- Artelo Biosciences (NASDAQ:ARTL) shares increased by 25.36% to $6.08. The company's market cap stands at $9.7 million.
- InspireMD (NASDAQ:NSPR) shares moved upwards by 13.96% to $2.04. The market value of their outstanding shares is at $75.8 million. The company's, Q4 earnings came out today.
- Citius Oncology (NASDAQ:CTOR) shares rose 13.63% to $0.87. The market value of their outstanding shares is at $67.5 million.
- CNS Pharma (NASDAQ:CNSP) shares increased by 11.06% to $2.51. The company's market cap stands at $1.4 million.
Losers
- OptimizeRx (NASDAQ:OPRX) stock declined by 15.3% to $5.61 during Wednesday's pre-market session. The company's market cap stands at $122.4 million.
- Lunai Bioworks (NASDAQ:LNAI) shares decreased by 12.4% to $0.49. The company's market cap stands at $13.4 million.
- bioAffinity Technologies (NASDAQ:BIAF) shares declined by 11.68% to $2.42. The market value of their outstanding shares is at $12.3 million. The company's, Q4 earnings came out 3 days ago.
- Akari Therapeutics (NASDAQ:AKTX) stock decreased by 11.67% to $0.19. The company's market cap stands at $7.7 million.
- GridAI Technologies (NASDAQ:GRDX) shares fell 11.47% to $1.93. The market value of their outstanding shares is at $7.3 million.
- EUDA Health Holdings (NASDAQ:EUDA) shares declined by 11.47% to $0.45. The market value of their outstanding shares is at $19.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.